Collegium Pharmaceutical (COLL) reported $188 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 29.4%. EPS of $1.68 for the same period compares to $1.62 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $180.38 million, representing a surprise of +4.23%. The company delivered an EPS surprise of +3.7%, with the consensus EPS estimate being $1.62.While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.70%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.43 per share when it actually produced earnings of $1.49, delivering a surprise of +4.2%.Over the ...

Collegium Pharmaceutical (COLL) Q2 2025 Earnings Call August 07, 2025 08:00 AM ET Speaker0At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I'll now turn the conference over to Ian Karp, Head of Investor Relations at Collegium.Thank you. You may now begin your presentation.Speaker1Great. Thanks and welcome to Collegium Pharmaceutical's second quarter twenty twenty five earnings conferenc ...

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this pre ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR (Exact name of registrant as specified in its charter) Virginia (State or other jurisdiction of incorporation or organization) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million ...

Group 1 - Collegium Pharmaceutical (COLL) closed at $32.11, with a 7.4% gain over the past four weeks, and a mean price target of $43 indicates a 33.9% upside potential [1] - The average price targets range from a low of $37.00 to a high of $50.00, with a standard deviation of $5.1, suggesting a variability in estimates; the lowest estimate indicates a 15.2% increase, while the highest points to a 55.7% upside [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as indicated by a 0.5% increase in the Zacks Consensus Estimate for the current year [4][11][12] Group 2 - COLL has a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - The consensus price target, while not entirely reliable, suggests a positive direction for price movement, which can guide further research into fundamental driving forces [14]

STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q ...

Group 1: Stock Buybacks Overview - Stock buybacks are effective for boosting share prices, especially when supported by strong fundamentals [1] - Companies with healthy balance sheets are combining repurchase plans with strategic capital returns to enhance shareholder value [1] Group 2: Collegium Pharmaceuticals - Collegium Pharmaceuticals focuses on pain management and is expected to see growing revenue and improving profitability in 2025 [2] - The company has a share count reduction of 20% year-over-year in Q1 and has authorized a new $150 million share repurchase [3] - Collegium's balance sheet shows increased cash, reduced intangibles, and flat assets, resulting in improved equity and leverage [4] Group 3: Enovix - Enovix initiated a $60 million buyback plan, which is significant as it exceeds the company's 2025 revenue outlook [6] - The company is expected to experience over 300% revenue growth by 2026, supported by improving manufacturing capabilities and market demand [7] - Enovix's balance sheet indicates a solid cash position of $248 million, equal to its total liabilities, allowing for comfortable share repurchases [7][8] Group 4: Thor Industries - Thor Industries has re-authorized a $400 million buyback plan, which represents over 8% of its market cap [11][12] - The company is experiencing growth and widening margins post-pandemic, providing sufficient cash flow to sustain buybacks and dividends [13] Group 5: Darden Restaurants - Darden Restaurants announced a $1 billion share repurchase authorization, representing 3.8% of its shares, alongside a dividend increase [16] - The decision to sell Bahama Breeze is expected to provide a cash injection and allow Darden to focus on its core business [17][18] Group 6: Fifth Third Bancorp - Fifth Third Bancorp reauthorized a buyback plan worth 100 million shares, with no expiration, to reduce share count quarterly [22] - The company has a robust dividend yield of 3.36%, expected to grow at a mid-single-digit pace annually [22] - Analyst sentiment is firming, with a consensus forecast predicting a 10% upside for the stock [23]

Core Viewpoint - The introduction of a "zero tariff" policy for imported medical devices and drugs in the Boao Lecheng International Medical Tourism Pilot Zone is facilitating the rapid entry of advanced medical technologies and products, benefiting both domestic and international patients [2][3]. Group 1: Policy Implementation - The "zero tariff" policy for imported medical devices and drugs was officially implemented on December 25, 2024, following the issuance of management measures by the Hainan provincial government [3]. - The Lecheng Pilot Zone has successfully integrated multiple departments to streamline the application process for "zero tariff" imports, reducing the administrative burden on medical institutions [4][6]. Group 2: Clinical Applications - The first clinical use of the Nexa smart cochlear implant system occurred at the Tree Lan (Boao) Hospital, with 50 units purchased, valued at approximately 15 million yuan, resulting in over 1 million yuan in tax exemptions [2][4]. - As of July 5, 2024, approximately 50 surgeries have been completed using the Nexa system, showcasing the immediate impact of the new policy on patient care [2]. Group 3: Regulatory Innovations - A comprehensive tracking management platform has been established to facilitate the application for "zero tariff" imports, allowing medical institutions to submit requests without leaving the hospital [3][4]. - The platform has enabled real-time data sharing between customs and medical institutions, enhancing efficiency and reducing redundancy in the application process [4][6]. Group 4: Future Developments - Continuous optimization of the platform and mechanisms is planned to expand the range of eligible medical devices and drugs, aiming to maximize the benefits of the policy for a larger population [7].